The closest FDA-approved IGF-1 product is mecasermin (Increlex) , native recombinant human IGF-1, approved only for the long-term treatment of growth failure in pediatric patients with severe primary IGF-1 deficiency or GH gene deletion with neutralizing antibodies
The pain is brief and typically well-tolerated
Ibrahim IA, Shalaby AA, Abd Elaziz RT, Bahr HI
Semaglutide GLP-1 is a significant development in the treatment of obesity
The test does not predict response to tirzepatide or any specific compound
By 48 weeks, significant average weight loss was seen at all maintenance doses: With longer treatment lasting up to 68 weeks, weight loss continued, particularly at higher doses: 12mg: average weight loss of up to 28.7% of body weight This longer-term data shows that weight loss with retatrutide can continue beyond one year, rather than plateauing early, especially at higher maintenance doses